Lanreotide is an SSA approved in >50 countries for the treatment of carcinoid syndrome.

**INTRODUCTION**

- Carcinoid syndrome occurs when a carcinoid tumor secretes certain amines and peptides that bypass the liver and are secreted into the bloodstream. This is usually the result of liver metastases. The most common symptoms are flushing and/or diarrhea.
- Somatostatin receptors are found on 80-90% of all carcinoid tumors.
- Somatostatin analogs (SSAs) are widely used to treat carcinoid syndrome.
- Lanreotide is an SSA approved in >50 countries for the treatment of carcinoid syndrome.
- In the US, it is currently approved for the treatment of acromegaly only.
- Somatuline® Depot injection is a prolonged-release formulation of lanreotide that is presented as a ready-to-use, pre-filled syringe administered via deep subcutaneous injection every 4 weeks.
- This ongoing clinical trial will evaluate the safety and efficacy of lanreotide versus placebo for the control of symptoms associated with carcinoid syndrome.

**STUDY OBJECTIVES**

- To evaluate the efficacy of lanreotide for the control of symptoms (diarrhea and/or flushing) associated with carcinoid syndrome.
- To characterize the effect of lanreotide versus placebo on biomarkers of tumor activity.
- To characterize the pharmacokinetic profile ($C_{min}$) of lanreotide in patients with carcinoid syndrome.
- To evaluate the safety of lanreotide.

**METHODS**

**Study design**

- Ongoing, multi-center, phase 3/4 study of patients with carcinoid syndrome with three phases (Figure):  
  - 16-week, double-blind, randomized, placebo-controlled phase
  - 32-week, open-label phase
  - long-term, open-label phase available for patients in countries where lanreotide is not yet approved for the treatment of carcinoid syndrome

**STUDY OBJECTIVES**

- To evaluate the efficacy of lanreotide for the control of symptoms (diarrhea and/or flushing) associated with carcinoid syndrome.
- To characterize the effect of lanreotide versus placebo on biomarkers of tumor activity.
- To characterize the pharmacokinetic profile ($C_{min}$) of lanreotide in patients with carcinoid syndrome.
- To evaluate the safety of lanreotide.

**METHODS**

- Ongoing, multi-center, phase 3/4 study of patients with carcinoid syndrome with three phases (Figure):
  - 16-week, double-blind, randomized, placebo-controlled phase
  - 32-week, open-label phase
  - long-term, open-label phase available for patients in countries where lanreotide is not yet approved for the treatment of carcinoid syndrome

**Study design**

- Double-blind phase: patients are randomized in a 1:1 ratio to one of the following treatments administered as a deep subcutaneous injection every 4 weeks:
  - 120 mg lanreotide
  - placebo (saline solution)
- Initial open-label and long-term open-label phases: all patients receive 120 mg lanreotide
- Throughout the study: patients are allowed to use subcutaneous octreotide, as needed, to control the symptoms associated with carcinoid syndrome (diarrhea and/or flushing).

**Primary endpoint**

- The usage (% of days) of subcutaneous octreotide required to control the symptoms (diarrhea and/or flushing) associated with carcinoid syndrome during the double-blind phase of the study.

**Participating countries**

- Brazil, Croatia, Czech Republic, India, Latvia, Poland, Russia, Serbia, South Africa, Turkey, Ukraine, and US

**Patients**

- Target enrollment: 100 patients

**Key inclusion criteria**

- Age ≥18 years at first dosing
- Histopathologically confirmed carcinoid tumor, or a carcinoid tumor of unknown location with liver metastases (documented by biopsy), and a history of carcinoid syndrome (diarrhea and/or flushing).
- SSA treatment naïve or responsive to conventional doses of octreotide.
- Willing to receive subcutaneous octreotide injections as rescue medication, as needed, to control symptoms associated with carcinoid syndrome.
- Confirmation of positive somatostatin receptor status.
- Documented absence of tumor progression.

**Key exclusion criteria**

- Treatment with interferon, chemotherapy and/or radiotherapy, a radiolabelled SSA and/or tumor debulking <3 months prior to study entry.
- Short bowel syndrome.
- Uncontrolled diabetes and/or hypertension.
- Severe renal and/or severe liver impairment.

**Key study assessments**

- Efficacy: symptoms and rescue medication use, biomarkers for tumor activity (plasma CgA, 5-HIAA), and a QoL questionnaire.
- Safety: physical exams, adverse events, biochemistry/hematology, gallbladder echography, electrocardiogram, and anti-lanreotide antibodies.

**Pharmacokinetics**

- Lanreotide serum concentrations are measured during the open-label phase at the following time points:
  - week 16: before and 4 hours after lanreotide administration
  - week 20: before lanreotide administration
  - week 48 (exit visit): at exit visit or before lanreotide administration if continuing into long-term, open-label extension.

**A total of 90 patients have been randomized to date; further recruitment is ongoing.**

**REFERENCES**